NeoPhore targets the dynamics of cancer neoantigen evolution and makes effective medicines that will become a key part of the next-generation of cancer immunotherapies.
Location: United Kingdom, England, Cambridge
Total raised: $44.66M
Investors 5
| Date | Name | Website |
| - | o2h ventur... | o2hventure... |
| 09.02.2024 | Neva SGR | nevasgr.co... |
| - | Club degli... | clubdeglin... |
| - | 3B Future ... | 3bfuturehe... |
| - | Parkwalk A... | parkwalkad... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 01.02.2024 | Series B | $12.17M | - |
| 19.01.2023 | Series B | $7.4M | - |
| 15.03.2021 | Series B | $21.13M | Claris Ven... |
| 16.11.2017 | - | $3.96M | - |
Mentions in press and media 11
| Date | Title | Description | Source |
| 01.02.2024 | NeoPhore Raises Additional £9.6M in Series B Extension Finan... | NeoPhore, a London, UK-based small molecule neoantigen immuno-oncology company, raised additional £9... | finsmes.co... |
| 01.02.2024 | United Kingdom-based Neophore raises GBP 9.5 million in fund... | London, United Kingdom-based small molecule neoantigen immuno-oncology company NeoPhore raised GBP 9... | vcbay.news... |
| 19.01.2023 | NeoPhore Closes £6M Extension to Series B; Round to £21.5M | NeoPhore, a Cambridge, UK-based small molecule neoantigen immuno-oncology company, raised £6M in an ... | finsmes.co... |
| 15.03.2021 | NeoPhore announces £15.2m financing to advance DNA mismatch ... | NeoPhore Limited, a small molecule neoantigen immuno-oncology company, has announced the close of a ... | cambridgen... |
| 15.03.2021 | NeoPhore announces £15.2m financing to advance DNA mismatch ... | NeoPhore announces £15.2m financing to advance DNA mismatch repair pipeline 15-03-2021 NeoPhore Limi... | cambridgen... |
| 12.03.2021 | NeoPhore: Cambridge startup secures £15M to develop advance ... | NeoPhore is a Cambridge-based company focused on the discovery and development of novel molecule the... | uktech.new... |
| 09.03.2021 | NeoPhore Closes £15.2M Series B Funding Round | NeoPhore Limited, a Cambridge, UK-based small molecule neoantigen immuno-oncology company, closed a ... | finsmes.co... |
| 09.03.2021 | NeoPhore Announces £15.2m Financing to Advance DNA Mismatch ... | Round led by Claris Ventures with 2Invest, 3B Future Health Fund and Astellas Venture Management | 3bfuturehe... |
| 16.11.2017 | NeoPhore Raises £3M in Funding | NeoPhore Ltd, a spin out from Cambridge, UK – based PhoreMost Ltd., focused on the discovery and dev... | finsmes.co... |
| - | NeoPhore | “NeoPhore targets the dynamics of cancer neoantigen evolution and makes effective medicines that wil... | fastfounde... |
Show more